Skip to Content
Merck
CN

Y0001101

Interferon β-1a

European Pharmacopoeia (EP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

CAS Number:
NACRES:
NA.24
UNSPSC Code:
41116107
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

pharmaceutical primary standard

API family

interferon

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

dry ice

storage temp.

−70°C

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Storage Class

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

常规特殊物品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Alemtuzumab for multiple sclerosis: who and when to treat?
Till Sprenger et al.
Lancet (London, England), 380(9856), 1795-1797 (2012-11-07)
Richard A C Hughes et al.
The Cochrane database of systematic reviews, 2(2), CD008630-CD008630 (2013-03-02)
Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and this update in 2013. To review systematically the evidence from
N N Spirin et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(8), 27-33 (2012-10-26)
Authors have followed up 230 patients with multiple sclerosis treated with disease modifying drugs (DMD) using the data of the Multiple sclerosis register of the Yaroslavl oblast during 2009-2011. Original drugs and their generics registered in Russia are used. Patients



Global Trade Item Number

SKUGTIN
Y000110104061833796993